Your browser doesn't support javascript.
loading
Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?
Najjar, Yana G.
Affiliation
  • Najjar YG; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA najjaryg@upmc.edu.
J Immunother Cancer ; 9(7)2021 07.
Article in En | MEDLINE | ID: mdl-34312244
Most patients with advanced melanoma ultimately fail immune checkpoint inhibitor (ICI) therapy because of primary or acquired resistance. There remains a critical unmet need for new therapies that function via alternative immune activation mechanisms to safely trigger an antitumor immune response in patients with ICI-refractory disease. This commentary discusses the recent failures and hope for novel intratumoral therapies under development in the advanced refractory melanoma setting, outlining key mechanistic differences that may be critical to yielding success in this difficult-to-treat population.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oncolytic Virotherapy / Immunotherapy / Melanoma Limits: Humans Language: En Journal: J Immunother Cancer Year: 2021 Document type: Article Affiliation country: United States Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oncolytic Virotherapy / Immunotherapy / Melanoma Limits: Humans Language: En Journal: J Immunother Cancer Year: 2021 Document type: Article Affiliation country: United States Country of publication: United kingdom